Ribomic Inc.

Tokyo Stock Exchange 4591.T

Ribomic Inc. Total Non-Current Liabilities for the year ending March 31, 2024

Ribomic Inc. Total Non-Current Liabilities is NA for the year ending March 31, 2024. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.
  • Ribomic Inc. Total Non-Current Liabilities for the year ending March 31, 2021 was USD 9.03, a 0.00% change year over year.
  • Ribomic Inc. Total Non-Current Liabilities for the year ending March 31, 2020 was USD 0.00.
Key data
Date Total Non-Current Liabilities Shareholders' Equity Other Liabilities Total Liabilities
Market news
SV Wall Street
Tokyo Stock Exchange: 4591.T

Ribomic Inc.

CEO Mr. Yoshikazu Nakamura Ph.D.
IPO Date Sept. 25, 2014
Location Japan
Headquarters Shirokanedai Usui Building
Employees 24
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.

StockViz Staff

February 10, 2025

Any question? Send us an email